Treatment conversations
Bone medications: fear, facts, and decision-making
Medication conversations can bring up fear, confusion, and strong opinions. A better conversation compares the risk of treatment with the risk of untreated fragile bone in a specific person.
The decision is personal, but it should not be vague
Osteoporosis medications can reduce fracture risk, but they do not cure bone fragility. They work best as part of a full plan that also includes fall prevention, strength, nutrition, medical evaluation, and follow-up.1
Main medication categories
| Category | Plain-language idea | Questions to ask |
|---|---|---|
| Antiresorptive medicines | Slow bone breakdown. This group includes bisphosphonates and denosumab. | Why this one, how long, what monitoring, what rare risks, and what happens when stopping? |
| Anabolic medicines | Help build bone. These may be discussed in very high-risk situations. | Am I high enough risk to consider this, and what treatment follows afterward? |
| Hormone-related options | Affect estrogen pathways or hormone context. | How do age, menopause timing, clot risk, breast cancer history, uterus status, and symptoms affect the decision? |
Fear deserves a careful answer
Rare side effects should be discussed honestly. So should the consequences of fractures. The goal is not to pressure anyone. The goal is to compare absolute risks: common outcomes like hip, spine, wrist, or shoulder fracture against uncommon medication harms, with duration, route, cost, monitoring, and stopping plans made explicit.2,3,5
Questions to bring
- What is my estimated fracture risk without medication?
- What outcome are we trying to prevent: hip fracture, spine fracture, another wrist fracture, or ongoing bone loss?
- Why this medicine rather than another category?
- How long would I take it, and what is the exit or transition plan?
- What side effects are common, and which rare risks should I understand?
- How will we know whether the plan is working?
Evidence review
Biology and benefit
Medication fear is understandable because rare harms are memorable. The evidence review has to keep two truths together: rare adverse events are real, and untreated high fracture risk is also real. The decision should compare absolute medication risk with absolute fracture risk, not compare a scary side effect with a vague idea of bone health.25
Rare harms
Atypical femur fracture and osteonecrosis of the jaw deserve careful explanation, especially with longer exposure or higher-risk clinical settings. But these risks should not be used to imply that osteoporosis treatment is generally more dangerous than fracture in patients at high risk.52
Stopping and switching
Some medicines require a plan at the beginning because stopping is not neutral. Denosumab discontinuation, for example, needs sequential antiresorptive therapy planning; otherwise, rebound bone loss and vertebral fracture risk can become part of the problem.63
Treatment strategy
A calm medication conversation should include expected benefit, rare but important harms, duration, monitoring, cost, route, adherence, dental context, kidney function, and what happens if the medication is stopped. After fracture, treatment decisions should also consider the risk of another fracture while healing and rehabilitation are underway.47
References
- Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364-376. doi:10.1016/S0140-6736(18)32112-3.
- Morin SN, Leslie WD, Schousboe JT. Osteoporosis: a review. JAMA. 2025. doi:10.1001/jama.2025.6003.
- Nayak S, Greenspan SL. A systematic review and meta-analysis of sequential treatment strategies for osteoporosis. Osteoporos Int. 2026. doi:10.1007/s00198-025-07717-5.
- Chandran M, Akesson KE, Javaid MK, et al. Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review. Osteoporos Int. 2024;35(10):1725-1738. doi:10.1007/s00198-024-07059-8.
- Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020;383(8):743-753. doi:10.1056/NEJMoa1916525.
- Queipo Menendez J, Garcia Tellado A, Pardo Lleidas J, Hernandez Hernandez JL. Hypercalcemia after denosumab discontinuation in patients with osteoporosis: a systematic review and case report. Osteoporos Int. 2026. doi:10.1007/s00198-026-07854-5. PMID:41571922.
- Hesari E, Sanjari M, Mansourzadeh MJ, et al. Osteoporosis medication adherence tools: a systematic review. Osteoporos Int. 2023. doi:10.1007/s00198-023-06789-5. PMID:37286664.
Educational Use Only
This website is educational. It is not a medical practice, telemedicine service, or a substitute for care from your own clinician.